Abstract:Objective: The purpose of this work was to improve EP solubility by using a sono-crystalization approach to reduce particle size and hence, increase the dissolution rate. Significance Eplerenone (EP) is an antagonist of the aldosterone receptor and is used for the treatment of hypertension and chronic heart failure. EP was classed as biopharmaceutical classification (BCS) class II because of its poor solubility and high permeability, which retards dissolution rate and drug absorption, and decreases bioavailability. Methods: Three-factors and two-level (2 3 ) multifactorial design have been employed to study the effect of independent variables which are drug concentration; (X1), stabilizer type (X2), and stabilizer concentration (X3) on responses; saturated solubility of EP in distilled water (Y1), saturated solubility in acidic media pH 1.2 (Y2), particle size (Y3), and polydispersity index, PDI (Y4). Also, they were characterized by Fourier transformed infrared spectroscopy (FTIR), Powder X-ray diffraction (PXRD), Differential scanning calorimetry (DSC), and yield percentage. The optimum formula was further subjected to an in-vitro release study. Results: The optimized formulation showed a saturated solubility of EP as 1.29, and 1.86 (mg/ml) in distilled water and acidic media (pH 1.2) respectively. Also, the particle size of 133 nm, and PDI of 0.824 with a small percentage of the difference between the observed and predicted values. Ninety-one percent of EP was released within 10 min., and it was completely released within 45 min. with a significantly higher release rate compared to raw drug. Conclusion: This work resulted in a satisfactory enhancement of solubility and dissolution rate which, is suitable for further in-vivo analysis. Graphical

Eplerenone Ethanol Solvate.

Crystal Structure of 9Α,11-Epoxy-7α-(methoxycarbonyl)-3-oxo-17α-pregn-4-ene-21,17-carbolactone

Eplerenone Tetrahydrofuran Solvate

Development of eplerenone nano sono-crystals using factorial design: enhanced solubility and dissolution rate via anti solvent crystallization technique

Ethyl (4ar,7s,8s,8as)-1-Oxo-7-Phenyl-3,4,4a,7,8,8a-Hexahydro-1h-Isochromen E-8-Carboxylate

(1R,4s,8r,9r,12s,13s,14r,16s,17r,19r)-17-[(ethylsulfanyl)methyl]-9,14-dihydroxy-7,7-dimethyl-2,18-dioxo-3,10-dioxapentacyclo[14.2.1.01,13.04,12.08,12]nonadecan-19-yl Acetate Acetone Solvate

Ethyl (4a<i>R</i>,7<i>S</i>,8<i>S</i>,8a<i>S</i>)-1-oxo-7-phenyl-3,4,4a,7,8,8a-hexahydro-1<i>H</i>-isochromene-8-carboxylate

4 Beta-Hydroxy-12,13-Epoxytrichothec-9-Ene

Crystal structure of (E)-13-{4-[(Z)-2-cyano-2-(3,4,5-tri-meth-oxy-phen-yl)ethen-yl]phen-yl}parthenolide methanol hemisolvate

Eupalinolide N, a Previously Undescribed Sesquiterpene Lactone with Anti-inflammatory Activity from Eupatorium Lindleyanum

20-O-β-d-xylopyranos-yl(1→6)-β-d-glucopyranosyl-20(s)-protopanaxadiol Methanol Solvate.

16 beta-bromo-17 alpha-hydroxypregn-4-ene-3,11,20-trione methanol solvate

(1S,3as,4s,7as)-Ethyl 1-Benzyl-2-(4-methoxybenzyl)-6,7-dimethyl-3-oxo-2,3,3a,4,5,7a-hexahydro-1h-isoindole-4-carboxylate Dichloromethane Monosolvate

AN EXPERIMENTAL DESIGN APPROACH FOR THE FORCED DEGRADATION STUDIES AND DEVELOPMENT OF A STABILITY-INDICATING LC METHOD FOR EPLERENONE IN TABLETS

Discovery of non-antiproliferative selective estrogen receptor degraders (SERDs) based on scaffold optimization of elacestrant

Evodialones A and B: Polyprenylated Acylcyclopentanone Racemates with a 3-Ethyl-1,1-diisopentyl-4-methylcyclopentane Skeleton from Evodia Lepta

16Β-Bromo-17α-hydroxypregn-4-ene-3,11,20-trione Methanol Solvate

3Β,12β,14α-Trihydroxypregnan-20-one

11Β,17aα-Dihydroxy-17aβ-methyl-d-homoandrosta-1,4-diene-3,17-dione Monohydrate

(E)-13-(4-Amino-phen-yl)parthenolide

Methyl 3Β-Methoxy-carbon-yloxy-4,4-di-methyl-17-oxo-16α-(3-oxobut-yl)-16β-carboxylate.